Compare Danaher Corporation (DHR) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares MSCI Germany (DAX) — how do they compare? Danaher Corporation trades at $206.46 (market cap $145.83B), while iShares MSCI Germany (DAX) trades at $43.83. The key difference: Danaher Corporation pays a 0.77% dividend while iShares MSCI Germany (DAX) pays none, and iShares MSCI Germany (DAX) is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | EWG | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $44.56 |
52-Week Low | $161.91 | $38.08 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
EWG trades at $43.815, down slightly by 0.13% on the day, with a bullish technical signal driven by moving averages but neutral oscillators. The stock lacks available fundamental data for valuation and profitability metrics. Recent news highlights European Central Bank policy and German economic developments influencing regional market sentiment.
The outlook remains tied to European economic trends and monetary policy. Risks include energy price volatility and geopolitical tensions, while opportunities may arise from German fiscal support and market rotations into European equities. Investors should assess fundamental data when available for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
